CXCL9 and metabolic dysfunction-associated steatohepatitis: Compared to healthy human livers, expression levels of CXCL9 and FABP4 are upregulated in human NASH livers, and BMP2, NRP1, and VEGFA are downregulated in livers from both NAFLD and NASH patients (Fig. 2C).